Short vs. long radiation therapy for rectal cancer
Treatments studied
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study compares two different radiation therapy schedules for rectal cancer that hasn't spread to distant sites. Researchers want to see if a shorter treatment plan works as well as a longer one, potentially reducing side effects and treatment time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Adenocarcinoma (a specific type of rectal cancer) confirmed by biopsy
- Cancer is within 10 cm of the anus and is locally advanced (stage T3–4 or involves lymph nodes)
- Cancer cells are MSS/pMMR type (a genetic marker showing the tumor responds well to standard treatment)
- No prior radiation, chemotherapy, or immunotherapy for this cancer
- Good overall health with adequate blood counts, liver, and kidney function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial tests a combination of focused radiation therapy given quickly, along with chemotherapy, targeted drugs, and immunotherapy before surgery for locally advanced rectal cancer. The goal is to shrink the tumor and improve survival chances by treating the cancer aggressively before an operation.
This study tests two different radiation regimens (long-course vs. short-course) combined with chemotherapy (CAPOX), an immunotherapy drug (PD-1 antibody), and a COX-2 inhibitor for people with MSS locally advanced rectal cancer. The goal is to see which approach works better in shrinking the tumor before surgery.
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This study is testing whether a short course of radiation combined with chemotherapy and an immunotherapy drug works better than the standard longer radiation and chemotherapy for early-stage rectal cancer that is low in the rectum. The goal is to see if this shorter treatment can help patients avoid surgery or have a better outcome.
Hear when a new Locally Advanced Rectal Cancer (LARC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.